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1   Introduction 
 
1.1 Hematopoiesis 
 
Under physiological conditions, blood cells have a limited life-span and are replaced by a 
newly produced population every day. In stress situations like bleeding or infection, blood 
cell production is increased returning to normal when the stress is over. This well-balanced 
process of blood cell production is termed hematopoiesis. Pluripotent hematopoietic stem 
cells are a very small subset of blood-forming cells, but they play a pivotal role in the 
maintenance of the hematopoietic system (Weissman, 2000). Once recruited into the cell 
cycle, the daughter cells of stem cells may take two different pathways: They may either 
undergo self-renewal to maintain the stem cell pool, or differentiate into committed 
progenitor cells which will undergo sequential cell divisions and finally give rise to 
functionally competent mature end cells. An adequate balance between stem cell self-renewal 
and differentiation is a prerequisite for the long-term maintenance of hematopoiesis. Recent 
observations highlight the importance of the hematopoietic microenvironment in this process 
(Dorshkind, 1990; Lichtman, 1981; Mayani et al., 1992b).  
 
1.2 The hematopoietic microenvironment and its in vitro model - the long-term bone 
marrow culture system 
 
While blood cells circulate freely throughout the body, proliferation and differentiation of 
hematopoietic stem cells are restricted to the hematopoietic tissues. In lethally-irradiated 
animals reconstituted with donor marrow cells, hematopoietic colonies exclusively develop 
within the bone marrow and the spleen (Till and McCulloch, 1961). Mice of strain Sl/Sld 
which have a congenital hypoplastic anemia as the result of a deficient hematopoietic 
microenvironment, can be cured by transfusion of allogeneic normal spleen tissue but not by 
normal hematopoietic stem cells (Bernstein, 1970). These facts suggest the existence of a 
regulatory hematopoietic microenvironment.  
 
In the early 1970’s, a bone marrow culture model was developed allowing the continued 
production of blood cells in vitro (Dexter et al., 1977). This long-term bone marrow culture 
system provided direct evidence for the regulatory function of the stromal microenvironment 
in the hematopoietic process. Long-term bone marrow cultures are liquid cultures containing 
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culture medium, horse serum, fetal bovine serum and bone marrow cells which, in the course 
of several weeks, form an adherent layer of predominantly non-hematopoietic cells on the 
bottom of the culture vessels. Hematopoietic stem cells burrow in the adherent layer, 
proliferate and, on phase-contrast microscopy, become visible as clusters of dark cells termed 
‘cobble stone areas’. Under the regulatory influence of the adherent layer the stem cells give 
rise to maturing hematopoietic cells which are being produced for a period of 8-12 weeks, 
followed by a gradual decline in cell production. After its initial description, several 
modifications have been made to adapt this culture system to the needs of specific scientific 
questions. Greenberger added hydrocortisone to the cultures in order to facilitate the 
development of a functional adherent layer which, in the absence of this hormone, is largely 
dependent on the batch of horse serum chosen (Greenberger, 1978).  In some mouse strains, 
myeloid cell production can thus be maintained for more than a year (Greenberger and 
Moloney, 1978). Growth of erythroid cells may be obtained by supplementing the cultures 
with anemic mouse serum (Dexter et al., 1981). If hydrocortisone and horse serum are 
omitted and β-mercaptoethanol is added to the cultures, B-lineage lymphoid hematopoiesis 
can be maintained and studied for prolonged periods of time (Whitlock and Witte, 1982).  
 
The long-term bone marrow culture system is considered to be the best in vitro model for 
hematopoiesis since it allows the production of blood cells in the absence of exogenously 
added growth factors. It has been reported that the cultures produce the whole range of 
differentiated progeny although further maturation is limited to the granulocyte lineage 
(Dexter, 1979). Eaves et al. reported that the most primitive hematopoietic stem cells are 
located within the stroma layer (Eaves et al., 1991). The primitive hematopoietic stem cells 
are maintained in a quiescent state if not perturbed, but they enter the cell cycle when the 
culture medium is changed (Cashman et al., 1985; Cashman et al., 1990). Whilst the 
nonadherent cell population in the supernatant is made up of terminally differentiated 
granulocytes and macrophages, clonogenic progenitor cells (particularly those differentiating 
along the granulocyte-macrophage lineage) can be detected both in the nonadherent and the 
adherent layer with continuous cycling irrespective of the timing of the medium change 
(Cashman et al., 1985).  
 
These observations imply the existence of a complex system of positive and negative 
regulatory factors orchestrating the distribution, differentiation, maturation and cycling 
behavior of different hematopoietic cell populations. Conclusive evidence has been presented 
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that these regulatory influences emanate from the adherent layer which constitutes the 
hematopoietic microenvironment in the long-term bone marrow cultures. The hematopoietic 
microenvironment is composed of hematopoietic and non-hematopoietic cells which secrete 
cytokines, elaborate adhesion molecules and produce the extracellular bone marrow matrix 
(Dorshkind, 1990; Lichtman, 1981; Mayani et al., 1992b; Verfaillie et al., 1994) . 
 
Similar to the bone marrow stroma in vivo, the adherent layer of a long-term bone marrow 
culture consists of four main cell types. The major components are fibroblasts and 
macrophages. Fibroblasts comprise 45 - 75% of the total cell number (Zhang et al., 1999) and 
may be subdivided into two distinct morphological subtypes, one having bipolar, spindle-cell 
morphology and the other a polygonal appearance. Both types have the ability to produce 
collagens I, II, III, IV, VI, VII, fibronectin, laminin, CD44, vascular cell adhesion molecule-1 
(VCAM–1), CD68, and a variety of cytokines. Macrophages are also present in significant 
numbers, comprising 25-35% of the adherent cells. Two morphological variants are 
recognized, one with round shape and abundant intracytoplasmic debris as evidence of 
phagocytosis, and the other with elongated and flattened shape lacking phagocytosed debris. 
Antigens expressed by stromal macrophages include CD14, CD35, CD44, CD68, VCAM-1, 
intercellular cell adhesion molecule-3 (ICAM-3), vimentin and granulocyte-macrophage 
colony-stimulating factor (GM-CSF) (Wilkins and Jones, 1995). Endothelial cells comprise 5 
- 20% of the cells of the adherent stroma layer. They contribute to the production of cytokines 
such as granulocyte colony-stimulating factor (G-CSF), macrophage colony-stimulating 
factor (M-CSF), GM-CSF, kit-ligand, interleukin-6 (IL-6) and leukemia inhibitory factor 
(LIF), and bind hematopoietic cells through integrins and selectins (Rafii et al., 1997). 
Adipocytes constitute a minor proportion of stroma cells. They are derived from adventitial 
reticular cells and can be induced by hydrocortisone (Gartner and Kaplan, 1980). Within these 
cell populations, fibroblasts, endothelial cells and adipocytes are of non-hematopoietic origin, 
while macrophages are derived from the blood-forming system (Agematsu and Nakahori, 
1991; Castro-Malaspina et al., 1980; Laver et al., 1987; Perkins and Fleischman, 1988).  
 
Although direct cell-to-cell contact has been shown to exist between stromal and 
hematopoietic cells by electron microscopy (Weiss, 1976) as well as electrophysiological and 
dye-transfer techniques (Dürig et al., 2000), other mechanisms are also important in the 
interaction between hematopoietic cells with the microenvironment including signalling via 
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soluble or cell-associated cytokines or interactions with the extracellular matrix produced by 
stroma cells.   
 
Early investigations failed to detect cytokines in significant amounts in unconcentrated stroma 
conditioned medium (Dexter et al., 1990; Williams et al., 1978). More recent data, however, 
point to the presence of both stimulatory and inhibitory hematopoietic growth factors in the 
long-term culture system (Deschaseaux et al., 1994; Eaves and Eaves, 1988; Gibson et al., 
1995; Gulati and Nath, 1994). Possible reasons for this controversy include 1) rapid 
utilization of growth factors in the cultures, 2) growth factors acting synergistically at low 
concentrations, and 3) binding of cytokines to stroma cell membranes or extracellular matrix 
proteins (Quesenberry et al., 1991). Further complexity is generated by the fact that 1) 
microenvironmental cells do not only produce hematopoietic cytokines but are also regulated 
by them (Table 1), 2) cytokines interact with each in such a way as to induce functional 
alterations, e.g. by interaction with other regulators stimulatory factors may turn into 
inhibitory ones or vice versa (Caux et al., 1990), and 3) some cytokines can regulate the 
proliferation and synthesis of the extracellular matrix components (Strobel et al., 1997), or 
conversely, some extracellular matrix components can induce the production of growth 
factors (Gordon, 1994). The complexity of the interactions between cells, cytokines and the 
extracellular matrix makes it difficult to clarify the exact mechanisms by which 
microenvironmental cells regulate hematopoietc cells.  
 
Table 1. Growth factors acting on or produced by bone marrow stroma cells 
Stroma cell type Factors acting on stroma cells Factors produced by stroma cells 
Fibroblasts IL-1, IL-6, IL-7, G-CSF, IFN-γ, 
PDGF, TGF-β, TNF-α 
IL-1, IL-6, IL-7, IL-8, G-CSF, M-CSF, 
GM-CSF, SCF, IFN-β 
Macrophages IL-1, IL-4, IL-8, TGF-β, TNF-α, 
M-CSF 
IL-1, IL-6, IFN-α, G-CSF, M-CSF,  
GM-CSF, PDGF, TGF-β, TNF-α 
Abbreviations: IL: interleukin; G-CSF: granulocyte colony-stimulating factor; M-CSF: macrophage CSF; GM-CSF: 
granulocyte-macrophage CSF; IFN: interferon; PDGF: platelet-derived growth factor; TGF: transforming growth factor; TNF: 
tumor necrosis factor; SCF: stem cell factor. 
 
Hematopoietic cells and non-hematopoietic stroma cells can produce a complex array of 
extracellular matrix molecules including collagens, proteoglycans and glycoproteins 
(Verfaillie et al., 1994). Collagens include types I, III, IV, and VI. They are thought to be 
produced by non-hematopoietic stroma cells. Other matrix molecules include fibronectin, 
laminin, thrombospondin and hemonectin (Giles et al., 2002). Proteoglycans are 
heterogeneous macromolecules consisting of a core protein and multiply sulphated side 
chains of repetitive disaccharide units, referred to as glycosaminoglycans. Forty percent of the 
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glycosaminoglycans are hyaluronic acid, others are composed of heparan sulfate, chondroitin 
sulfate or dermatan sulfate. Glycoproteins may act as cell adhesion molecules. They are 
expressed by both hematopoietic and non-hematopoietic cells and fall into six structurally 
distinct superfamilies including integrins, selectins, sialomucins, immunoglobulins, CD44 and 
cadherins.  
 
The mechanisms by which extracellular matrix molecules participate in the regulation of 
hematopoiesis are complex. First, they provide an anchor site for hematopoietic cells. Second, 
they function locally as stimulatory or inhibitory factors (Nilsson et al., 2003; Siczkowski et 
al., 1992; Weinstein et al., 1989; Wight et al., 1986). Third, they may be shed into the culture 
medium where they may act as soluble regulatory factors (Gupta et al., 1996). Fourth, they 
may indirectly regulate hematopoiesis by binding cytokines secreted by stroma cells (Gordon 
et al., 1987; Roberts et al., 1988). 
 
The hematopoietic microenvironment is of pivotal importance for the function of 
hematopoietic stem cells. Schofield developed the concept of the ‘stem cell niche’ (Schofield, 
1978) which assumes that the capacity of the progeny of pluripotent hematopoietic stem cells 
to retain their pluripotentiality is not an intrinsic property of the stem cells proper, but the 
result of an interaction with specific sites within the hematopoietic microenvironment in 
which the stem cells lodge. A daughter cell, if placed in a stem cell niche, would remain 
pluripotent. If a daughter cell were to migrate from the niche, it would acquire an increasing 
probability of differentiation. The concept of specific niches in the microenvironment has 
subsequently been refined and extended by other investigators (Verfaillie, 1998). Selective 
adhesion of cells of a certain developmental stage to extracellular matrix components or 
stroma cells will result to exposure to specific conditions (‘milieu’) which will be conducive 
to the development of the cells. Thus, the orderly progression of hematopoiesis may be 
guaranteed by the transition of cells from one type of niche to another.  Evidence has been 
presented that, in vivo, stem cells preferentially lodge close to the osteoblast-rich endosteal 
surface (Calvi et al., 2003; Zhang et al., 2003). As differentiation and maturation proceed, the 
cells are migrating closer to the center of the marrow cavity where they enter the blood stream. 
 
In summary, hematopoiesis is a complex process in which pluripotent stem cells proliferate 
and differentiate to generate the different compartments of mature blood cells. Four main 
types of stroma cells, more than 30 hematopoietic cytokines, more than 20 different adhesion 
molecules and a complex extracellular matrix constitute an interactive network, the so-called 
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hematopoietic microenvironment, which is the anatomical and functional basis for long-term 
balanced hematopoiesis.  
 
 
1.3 Functional analysis of the hematopoietic microenvironment in vitro 
 
Depletion of long-term bone marrow cultures of hematopoietic cells leads to the generation of 
pure stroma layers whose overall hematopoiesis-supporting function may then be analysed 
using standardized indicator cells. In these so-called ‘two-stage long-term bone marrow 
cultures’, stroma layers are grown from bone marrow samples of interest, irradiated to 
eliminate the endogenous hematopoiesis, and recharged with a standard inoculum of indicator 
cells (usually bone marrow mononuclear cells or purified progenitor cells). This provides the 
possibility to study the effect of the stroma on the maintenance of very primitive progenitor 
cells without the confounding effects of an ill-defined mixture of hematopoietic cells. The 
most commonly used endpoint is to measure the number of colony-forming hematopoietic 
cells which are generated after a 5-week culture period on the irradiated stroma layer.  
Although not identical, this endpoint yields similar results to those obtained using more 
cumbersome assay systems such as limiting dilution analysis or the enumeration of cobble 
stone area forming cells (Sutherland et al., 1989). All three endpoints are commonly used as a 
surrogate marker for hematopoietic stem cells. When the number of indicator cells added to 
the adherent layer is kept constant, the number of colony-forming cells in the cultures after 5 
weeks is a quantitative measure for the hematopoiesis-supporting capacity of the stroma. 
 
 
1.4  The hematopoietic microenvironment in hematological malignancies 
 
Hematological malignancies are clonal disorders resulting from neoplastic transformation of 
hematopoietic stem or progenitor cells. Similar to their normal counterparts, proliferation and 
differentiation of the transformed cells still underlie modulation by the hematopoietic 
microenvironment.  The transformed cells and their progeny infiltrate the hematopoietic 
microenvironment and their products such as cytokines, extracellular matrix components, 
adhesion molecules or material transferred by direct cell-cell contact may influence the 
function and composition of the stromal microenvironment. Schematically, the 
microenvironment may be affected in three different ways in hematological malignancies 
(Dührsen and Hossfeld, 1996):  
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1) Neoplastic cells induce reversible changes in stroma function or composition which 
may favor the growth of malignant cells (‘malignancy-induced microenvironment’).  
2) Elements of the malignant clone become part of the stroma. Sometimes they 
preferentially promote the growth of neoplastic cells and inhibit the proliferation of 
normal cells (‘malignant microenvironment’).  
3) A primary stromal abnormality causes an inability to control regular blood cell 
formation which favors the emergence of ‘opportunistic’ neoplastic cell clones 
(‘malignancy-inducing microenvironment’). 
 
 
1.5 Goals of the present investigation 
 
The goal of the present investigation was to describe and compare alterations in stroma 
function in distinct hematological malignancies, and by use of cell fractionation techniques, 
identify the types of stroma cell responsible for these alterations. To this end we chose three 
hematological neoplasms all of which were characterized by bone marrow infiltration, but 
which  differed in a number of other parameters. 
 
Acute myeloid leukemia (AML) is a stem or progenitor cell disease with replacement of 
normal hematopoiesis by leukemic blasts. The disease is heterogeneous with respect to 
cytogenetic and immunophenotypic characteristics. According to the ‘French-American-
British’ (FAB) classification it is subdivided into seven morphological subtypes. 
Abnormalities involve both the myeloid, erythroid and megakaryocytic lineages for which the 
long-term bone marrow culture condition provides very good growth conditions, thus making 
it a good model for hematopoietic changes occurring in AML in vivo. 
 
Despite heterogeneous genetic, morphological, biological and clinical features, all forms of 
myelodysplastic syndromes (MDS) are considered to be hematopoietic stem cell disorders 
accompanied by ineffective hematopoiesis and multi-lineage cytopenia. According to the 
FAB classification five different types of MDS may be distinguished. This group of diseases 
constitutes a preleukemic disorder in which the neoplastic clone may or may not progress to 
full-blown acute leukemia. Due to a large number of common features between AML and 
MDS, many hematologists consider them as parts of a continuous disease spectrum rather 
than distinct disorders. 
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 Multiple myeloma (MM) is a post-germinal center B-cell tumor with a clonal proliferation of 
transformed plasma cells in the bone marrow. Osteolytic bone lesions, anemia, 
immunodeficiency and renal impairment constitute the main features of this disease. Being a 
lymphoid neoplasm multiple myeloma is clearly distinct from AML and MDS. 
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2 Patients, materials and methods 
  
2.1 Patients  
Bone marrow samples were obtained with informed consent from patients undergoing 
diagnostic bone marrow biopsy. In general, the number of cells harvested was sufficient to 
prepare one set of cultures as described in section 2.4 and Figure 1. Parallel cultures proving 
reproducibility of the experimental procedure were limited to patients with particularly ample 
bone marrow aspirates (cf. 3.1.2.4).  
 
2.1.1  Control subjects 
The control subjects underwent bone marrow biopsy for untreated lymphoma or other 
diseases. Morphology and surface marker expression using a fluorescence-activated cell 
analyser were employed to exclude bone marrow involvement.  The clinical details of 11 
patients used as controls in section 3.1 and 17 patients used as controls in section 3.2 are 
listed in Tables 2 and 3, respectively. The age of this population ranged from 20 to 84 years 
(median 59), and there were 15 males and 13 females. 
 
2.1.2  Patients with acute myeloid leukemia 
Unless otherwise stated, all cases of AML were newly diagnosed fulfilling the diagnostic 
criteria of the FAB classification (Bennett et al., 1976). The clinical details of 6 patients 
analysed in section 3.1 and 15 patients analysed in section 3.2 are listed in Tables 4 and 5, 
respectively. The age of this population ranged from 33 to 80 years (median 65), and there 
were 7 males and 8 females.  
 
2.1.3  Patients with myelodysplastic syndromes 
The diagnosis of MDS was based on the criteria of the FAB cooperative group (Bennett et al., 
1982). Three of the patients were newly diagnosed, three had long-standing disease, and none 
had received chemotherapy. In this group, the age range was 60 to 77 years (median 67), and 
there were 4 males and 2 females (Table 6). 
 
2.1.4  Patients with multiple myeloma 
All multiple myeloma patients were untreated and in stage III according to the criteria of the 
Southwest Oncology Group (Durie and Salmon, 1975). The clinical details are given in Table 
7. The age ranged from 47 to 67 years (median 59), and there were 5 males and 4 females. 
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Table 2. Clinical and hematological data of control patients studied in section 3.1 
Patients Peripheral blood counts 
No. Initials Age (years) Gender Disease WBC x 109/L Hb g/dL Platelets x 109/L
1 BE 66 F DLBCL 5.5 12.9 313 
2 SKH 58 M MCL 7.5 9.4 133 
3 PT 55 M DLBCL 4.7 10.8 302 
4 BS 32 M DLBCL 5.6 14.7 293 
5 GO 82 M DLBCL 8.2 14.8 154 
6 HU 56 M HD 11.6 10.8 297 
7 AM 20 F HD 7.0 13.7 429 
8 RD 55 F Osteomyelitis 6.9 14.2 317 
9 RG 67 F Polyarthritis 4.6 11.3 80 
10 BU 32 M Splenomegaly 6.7 14.5 244 
11 SG 64 F B-NHL 11.6 12.7 252 
 
 
 
 
 
 
 
 
 
Table 3. Clinical and hematological data of control patients studied in section 3.2 
Patients Peripheral blood counts 
No. Initials Age (years) Gender Disease WBC x 109/L Hb g/dL Platelets x 109/L
1 SM 70 M DLBCL 6.3 14.3 225 
2 MH 50 M Cutaneous FL 9.3 14.9 194 
3 WKD 69 M T-NHL 5.5 14.0 249 
4 BM 85 F MZL 6.8 13.9 270 
5 KA 76 F MZL 9.2 14.0 231 
6 OM 53 M FL 13.4 12.5 309 
7 BE 64 F Iron Deficiency 4.9 10.2 181 
8 SK 24 F HD 13.7 12.5 434 
9 RE 84 M Cutaneous T-NHL 7.4 13.3 214 
10 PH 62 F B-NHL 15.7 13.7 227 
11 BJ 62 M PCNSL 8.6 14.5 185 
12 BM 39 M DLBCL 9.1 13.6 356 
13 RI 38 F HD 6.4 11.3 285 
14 WK 59 F Burkitt’s NHL 5.9 11.6 78 
15 VL 37 M HD 6.5 15.3 275 
16 HE 36 M Leukopenia 3.6 16.0 197 
17 DB 59 F Leukopenia 3.1 11.7 184 
 
Abbreviations in Tables 2 and 3: DLBCL: diffuse large B cell lymphoma; F: female; FL: follicular lymphoma; Hb: 
hemoglobin; HD: Hodgkin’s disease; M: male; MCL: mantle cell lymphoma; MZL: marginal zone lymphoma; NHL: non-
Hodgkin’s lymphoma; PCNSL: primary central nervous system lymphoma; WBC: white blood cells. 
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Table 4. Clinical and hematological data of newly diagnosed AML patients studied in section 3.1 
Patients Disease characteristics Peripheral blood counts
 
No. 
 
Initials 
Age 
(years) 
 
Gender 
 
FAB type
 
Marrow cytogenetics 
WBC  
x 109/L  
Hb 
g/dL 
Platelets
x 109/L
1 HB 58 F M2 t(8;21)(q22;q22) 10.8 10.1 69 
2 PA 53 F M1 Normal 17.8 9.9 216 
3 FRJ 32 M M4 t(10;14)(p13;q22) 21.1 11.1 65 
4 PSBG 69 F M4 +3, +8, del(21) 25.6 11.8 95 
5 WW 50 M M0 t(4;12)(q11;p13) 96.3 10.4 269 
6 DP 41 F M4 +8, t(9;11)(p21-22;q23) 30 9.2 31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Clinical and hematological data of newly diagnosed AML patients studied in section 3.2 
Patients Disease characteristics Peripheral blood counts
 
No. 
 
Initials 
Age 
(years) 
 
Gender 
 
FAB type
 
Marrow cytogenetics 
WBC 
x 109/L 
Hb 
g/dL 
Platelets
x 109/L
1 WL 50 F M4 Normal 93 9.2 76 
2 TR 68 F M4 t(1;5)(p32;q35) 96 9.8 60 
3 DK 80 F M4 inv(16)(p13q22) 20.5 13.0 53 
4 DGV 71 F M5 Normal 47.5 10.5 101 
5 RA 65 M M1 t(1;8)(p36;q24.1), t(5;15),  
add(19)(q13) 
3.7 9.4 60 
6 ME 53 M M2 add(11) 17.1 7.3 106 
7 GR 63 M M4 +X, +Y, -6, -21, add(21)(q13) 2 8.2 20 
8 FM 70 F M4 -X, +8, t(8;21)(q22;q22) 8.4 7.2 34 
9 IM 72 M M4 +8 36.2 9.7 36 
10 GA 80 F M4 Normal 14.4 7.8 29 
11 ZD 66 F M4 Normal 1.5 9.1 162 
12 FR 42 M M1 -Y, -2, del(3)(p12), del(7)(q21q31), 
-11, -12, +3mar 
9.2 5.5 7.5 
13 BH 37 F M2 Normal 21.1 8.5 71 
14 RJ 45 M M4 Normal 2.5 11.6 328 
15 BV 33 M M0 Normal 31 8.0 47 
 
Abbreviations in Tables 4 and 5: F: female; FAB: French-American-British classification; Hb: hemoglobin; M: male; WBC: 
white blood cells. 
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Table 6. Clinical and hematological data of MDS patients studied 
Patients Disease characteristics Peripheral blood counts
 
No. 
 
Initials 
Age 
(years) 
 
Gender 
 
FAB type
 
Marrow cytogenetics 
WBC 
x 109/L 
Hb 
g/dL 
Platelets
x 109/L
1 CG 77 M RA -Y 2.0 10.8 88 
2 TG 65 F RARS Normal 4.8 11.4 194 
3 PM 70 M RA del(13q)(q12q14) 9.9 11.1 141 
4 RW 60 F RARS Normal 6.6 11.0 386 
5 KC 67 M RA -Y, +8  5.1 6.7 58 
6 PR 67 M RAEB del(3)(p11p21), -4, -5, -9, +mar 3.7 8.1 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7. Clinical and hematological data of newly diagnosed multiple myeloma patients studied 
Patients Disease characteristics Peripheral blood counts
 
No. 
 
Initials 
Age 
(years) 
 
Gender 
Monoclonal 
immunoglobulin 
 
Renal disease
 
Osteolyses
WBC 
x 109/L 
Hb 
g/dL 
Platelets
x 109/L
1 HH 51 F IgG lambda No Yes 12.2 8.3 618 
2 SKH 67 M IgG kappa No Yes 7.1 12.3 310 
3 PL 62 M IgG kappa No No 8.4 12.6 323 
4 SM 59 M Light chain kappa No Yes 8.5 8.5 468 
5 KC 48 M IgG lambda Yes Yes 7.9 7.6 238 
6 GB 55 F Light chain lambda Yes Yes 5.3 7.1 102 
7 SU 65 F Light chain lambda Yes Yes 6.0 8.0 399 
8 KI 47 F IgG lambda No Yes 16.1 14.7 411 
9 SK 59 M IgG kappa Yes Yes 6.0 9.5 102 
 
Abbreviations in Tables 6 and 7: F: female; FAB: French-American-British classification; Hb: hemoglobin; M: male; Ig: 
immunoglobulin; RA: refractory anemia; RAEB: refractory anemia with excess of blasts; RARS: refractory anemia with 
ringed sideroblasts; WBC: white blood cells. 
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2.2  Culture media 
 
Iscove’s modified Dulbecco’s medium (IMDM) 350 
17.66g  IMDM      Invitrogen Coorperation 
10 ml  Penicillin-streptomycin   Invitrogen Coorperation 
35 ml  Sodium bicarbonate    Sigma 
805 ml  H2O 
 
Long-term bone marrow culture medium 
 800 ml  IMDM 350 
 100 ml  Fetal Bovine Serum (FBS#06450)  StemCell Technologies 
 100 ml  Horse Serum (HS#06750)   StemCell Technologies 
 5×10-7 M Hydrocortisone    Sigma 
 
M2-10B4 medium 
85 ml  RPMI1640     Sigma 
15 ml  Fetal Calf Serum (FCS A15-043)  PAA Laboratories 
1 ml  10,000 U/ml Penicillin-streptomycin  Invitrogen Coorperation 
2 ml  200 mM L-Glutamine    Invitrogen Coorperation 
 
Fibroblast medium 
 85 ml  IMDM350 
 15 ml  Fetal Bovine Serum (FBS#06472)  StemCell Technologies 
 
Methylcellulose and growth factors for colony assays 
 80 ml  MethylCult H4230    StemCell Technologies 
 0.03ug/ml rh GM-CSF     PeproTech 
 0.03ug/ml rh G-CSF     PeproTech 
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2.3 Magnetic cell separation (MACS) equipment and other reagents 
 
MACS beads 
 CD14 MicroBeads      Miltenyi Biotec  
 Anti-Fibroblast MicroBeads     Miltenyi Biotec 
 Direct CD34 progenitor cell isolation kit   Miltenyi Biotec 
  
MACS instruments 
MACS large cell separation columns    Miltenyi Biotec 
MACS magnetic field      Miltenyi Biotec 
 
MACS buffer 
95 ml  Phosphate-buffered saline (PBS)  Gibco 
5 ml  Bovine serum albumin (BSA)  StemCell Technologies 
2 mM  EDTA      Sigma 
 
Other reagents 
Ammonium chloride lysing reagent     PharMingen 
Trypsin / EDTA (10×)      PAA Laboratories 
 MethylCult H4100       StemCell Technologies 
 
 
2.4 Cell cultures 
 
2.4.1   Primary long-term bone marrow cultures 
Bone marrow samples were obtained by aspiration from the posterior iliac crest and collected 
in heparin-containing tubes. Samples were processed within four hours after aspiration. The 
marrow was diluted 1 : 1 with PBS, mixed with methylcellulose at a final concentration of 
0.1% and placed at room temperature for 35-40 minutes to promote red cell separation by 
gravity sedimentation. The top layer containing the nucleated cell fraction was collected, 
washed once in PBS and subjected to erythrocyte lysis using ammonium chloride lysing 
reagent. The cells were then seeded at a density of 2×106 cells per ml in 5 ml long-term bone 
marrow culture medium in T 12.5 cm2 tissue culture flasks (Coutinho et al., 1986). Parallel 
cultures were prepared to obtain sufficient numbers of adherent cells. For the first week, the 
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cultures were incubated at 37°C in a 95% humidified atmosphere of 5% CO2 in air and then 
transferred to 33°C for another 2-3 weeks until a confluent adherent layer had formed. The 
cultures were maintained by weekly demi-depopulation and substitution of half the spent 
medium by an equal volume of fresh medium (Coutinho et al., 1986).  
 
2.4.2 Two-stage long-term bone marrow cultures 
The entire experimental procedure is shown in Fig. 1. Details of the methods are described 
below. 
 
2.4.2.1 Establishment of an adherent stroma layer  
After three to four weeks of cultivation, most cultures developed a confluent stroma layer. 
Confluency of cultures was evaluated under the inverted microscope by dividing the flask 
bottom into twenty equal squares and counting the proportion of squares occupied by the 
adherent layer. Cultures with a confluency of more than 15% were used for the subsequent 
steps.  
 
2.4.2.2 Depletion of endogenous hematopoietic cells by irradiation of the stroma layer 
In one part of the study, one of the culture flasks from each marrow sample was exposed to 15 
Gy irradiation (250 kV peak x-ray) to eliminate endogenous benign and malignant 
hematopoietic cells. The supernatant was subsequently replaced by fresh long-term bone 
marrow culture medium (Coutinho et al., 1986).  
 
2.4.2.3 Fractionation of the stroma by immunomagnetic cell separation  
In another part of the study, one or more flasks from each marrow sample were used for the 
isolation of stroma fibroblasts and macrophages using immunomagnetic techniques. 
Confluent stroma was washed thoroughly with PBS to eliminate non-adherent cells, and then 
detached by adding 1.5 ml of a 0.25% trypsin/PBS solution followed by incubation in 37°C 
for 5 minutes and addition of an equal volume of ice-cold FCS to neutralize trypsinization. In 
order to obtain a single cell suspension without cell clumps, the sheets of detached adherent 
cells were passed through a 30 µm nylon mesh followed by vigorous pipetting. Cells were 
counted using a hemocytometer, and aliquots of 107 cells were resuspended in 80 µl buffer. 
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2.4.2.4 Establishment of a pure fibroblast stroma layer 
20 µl MACS anti-fibroblast microbeads were added to 107 trypsinized stroma cells suspended 
in 80 µl buffer and incubated for 30 minutes at 20° to 25°C. Subsequently, the cells were 
passed through a MACS large cell separation column placed in a magnetic field. Antibody-
labelled cells were detained in the column while unlabelled cells passed through. Positive 
cells were collected by removal of the column from the magnetic field and flushing with 
buffer. To evaluate the purity of the isolated cell populations cytospins were prepared and 
stained with May-Grünwald-Giemsa. Stroma fibroblasts were identified as cells with large 
irregular euchromatic nuclei and blue cytoplasm. Stroma macrophages were identified as cells 
with small round heterochromatic nuclei and vacuolated cytoplasm. Only separations with 
more than 92% purity were used for the subsequent steps in the experimental protocol. The 
isolated stroma fibroblasts were cultured in fibroblast medium at 37°C in a 95% humidified 
atmosphere of 5% CO2 in air until reaching confluency.  
 
2.4.2.5 Establishment of a stroma layer composed of macrophages and M2-10B4 cells 
Since macrophages fail to form a confluent adherent layer and are unable to support long-term 
hematopoiesis in the absence of other stroma cell types, the effect of macrophages on the 
performance of the microenvironment was analysed by co-culturing isolated human stroma 
macrophages with murine M2-10B4 cells which have been shown to support human 
hematopoiesis in vitro (Sutherland et al., 1991). M2-10B4 cell cultures without added 
macrophages served as a control in these experiments. 
 
In order to obtain pure stroma macrophages 20 µl MACS CD14 microbeads were added to 80 
µl of a suspension containing 107 detached stroma cells. After incubation at 6° to 12°C for 15 
minutes, the cells were passed through a MACS large cell separation column placed in a 
magnetic field. Antibody-labelled cells were detained in the column while CD14-negative 
cells passed through. Positive cells were collected by removal of the column from the 
magnetic field and flushing with buffer. Cytospins were prepared to evaluate the efficacy of 
the fractionation procedure. The isolated stroma macrophages were plated on top of irradiated 
M2-10B4 cultures at a concentration of 3 × 105 cells per 5 ml long-term bone marrow culture 
medium in a T 12.5 cm2 flask.  
 
M2-10B4 cells were maintained in T 12.5 cm2 tissue culture flasks in M2-10B4 medium and 
passaged once they got confluent. To this end old medium was decanted, confluent stroma 
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was washed once with PBS, and 1.5 ml of a 0.25% trypsin/PBS solution was added. After an 
incubation period of 5 minutes at 37°C the enzymatic reaction was stopped by addition of 1.5 
ml of ice-cold FCS. Cells were washed once and counted. 4 × 105 cells were resuspended in 5 
ml of M2-10B4 medium, transferred to a new T 12.5 cm2 flask and incubated for 3 days at 
37°C in a 95% humidified atmosphere of 5% CO2 in air to achieve confluency. In order to 
create comparable conditions for each set of experiments several flasks were prepared in 
parallel. To prevent overgrowth and stop cell division confluent M2-10B4 cultures were 
irradiated with 30 Gy using the same apparatus as used for human long-term cultures. After 
irradiation the M2-10B4 medium was replaced by long-term bone marrow culture medium.  
   
2.4.2.6 Purification of CD34+ indicator cells 
Human CD34+ cells served as indicator cells for the hematopoiesis-supporting function of the 
stroma and its isolated cellular constituents. CD34+ cells were obtained with informed 
consent from excess leukapheresis material from a patient with multiple myeloma undergoing 
autologous stem cell transplantation. CD34+ cells were selected by MACS separation using a 
direct CD34 progenitor cell isolation kit. In principal, separation followed the same protocol 
as described for the isolation of fibroblasts and macrophages. The purity of the separated cells 
as assessed by fluorescence-activated cell analysis was more than 96% (data not shown). 
Aliquots of cells were preserved in liquid nitrogen for long-term use.  
 
2.4.2.7 Co-culture of CD34+ cells with a pre-established adherent layer 
2.5 × 104 CD34+ cells were seeded onto different types of pre-established stroma layers 
including unfractionated irradiated long-term culture layers, pure fibroblast layers, irradiated 
M2-10B4 layers alone and irradiated M2-10B4 layers with purified human stroma 
macrophages. The co-cultures were maintained in T 12.5 cm2 tissue culture flasks in 5 ml 
long-term bone marrow culture medium at 33°C in a 95% humidified atmosphere of 5% CO2 
in air for 5 weeks with weekly half-medium change as described above. After 5 weeks of co-
culture, both non-adherent and adherent cells were collected, counted and plated in 
methylcellulose cultures for the enumeration of granulocyte-macrophage colony-forming cells 
(CFC). The sum of the CFC in the non-adherent and adherent cell fractions at week 5 were 
termed W5 CFC. 
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2.4.2.8 Colony assays in methylcellulose cultures 
An appropriate number of cells harvested from long-term cultures were mixed with 1 ml of G-
CSF and GM-CSF supplemented 2.6% methylcellulose medium, plated in triplicates in 24-
well plates and incubated for 14 days at 37°C in a 95% humidified atmosphere of 5% CO2 in 
air. On day 14, colonies (defined as cell aggregates of more than 40 cells) were scored using 
an inverted microscope. 
 
 
2.5 Statistical analysis 
A non-parametric Mann-Whitney U test was used to compare W5 CFC values between 
groups. Wilcoxon analysis was used to compare paired samples. Correlation analysis was 
assessed using Spearman analysis for asymmetrically distributed samples. P values below  
0.05 were considered to demonstrate statistically significant results. All calculations were 
done using the SPSS 10.0 software (SPSS, Chicago, IL, USA). 
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3 Results 
 
3.1 Stroma function in acute myeloid leukemia 
 
3.1.1 Primary long-term bone marrow cultures 
Confluent stroma was obtained after three to four weeks of culture. There was no statistically 
significant difference in the degree of confluency between normal (70 ± 28%, range 30 - 
100%) and AML stroma (61 ± 31%, range 15 - 100%). However, subtle morphological 
differences were observed under the inverted microscope as shown in Figure 2. In normal 
long-term cultures, abundant adipocytes and ample cobble stone area formation were seen 
representing the growth of stem and early progenitor cells in the stroma layer. By contrast, 
adipocytes were scarcely seen in the stroma of AML cultures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: Primary long-term culture stroma from a normal individual (left) and an AML patient (right).  The
left picture shows abundant adipocytes (arrows) besides patches of cobble stone areas (solid circles with
dotted lines), while the right picture shows no adipocytes and few hematopoietic foci although the stroma
was fully confluent. (Phase-contrast inverted microscope, original magnification *100) 
 
The hematopoiesis-supporting function of the stroma was assessed by counting the number of 
nucleated cells removed during weekly demi-depletion of the cultures and determining the 
number of colony-forming cells in G-CSF and GM-CSF stimulated methylcellulose cultures. 
Figure 3a shows the behavior of total nucleated cells in the supernatant of the cultures. AML 
cultures were clearly different from normal cultures showing two different growth patterns. In 
pattern 1 (2 patients) cell numbers were persistently higher than in the control group. In 
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pattern 2 (4 patients) the cell numbers remained in the same range as in the control cultures 
during the first four or five weeks, with a rapid decline below the normal range at later time 
points. While in the control group all curves showed a plateau after the first three weeks of 
culture, a continuous decline until the end of the culture period was observed in the group of 
AML patients displaying pattern 2.  
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 Fig. 3a: Numbers of nucleated cells in the supernatant of long-term bone marrow cultures from 6
AML patients (solid lines) and 8 controls (dotted lines) during an 8-week incubation period.  
 
 
Granulocyte-macrophage colonies were enumerated according to established criteria. In the 
methylcellulose cultures from some AML patients morphologically abnormal colonies or 
clusters (i.e. cell aggregates of fewer than 40 cells) were observed. These colonies or clusters 
were thought to originate from the proliferation of leukemic blasts and made an accurate 
enumeration of normal colonies impossible. Figure 3b shows the weekly output of 
granulocyte-macrophage colony-forming cells (CFC) in the supernatant of control and AML 
cultures. Again, the AML group displayed two different growth patterns. Pattern 1 showed a 
persistently higher output of CFC compared with the control cultures. Pattern 2 showed a 
sharp decline after the second week of cultivation with few if any CFC remaining thereafter. 
In the methylcellulose cultures of the two patients with the first pattern, most colonies and 
clusters showed an abnormally diffuse morphology and their size was highly variable, 
 
suggesting that they represented the growth of leukemic blasts. In such cultures colonies of 
normal morphology were virtually not observed.  
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Fig. 3b: Numbers of colony-forming cells in the supernatant of long-term bone marrow cultures
from 6 AML patients (solid lines) and 8 controls (dotted lines) during an 8-week incubation period. 
 
 colony-forming cells in the non-adherent cell fraction are considered to be less good a 
ameter for the hematopoiesis-supporting function of the stroma than the colony-forming 
s in the adherent layer which contains the most primitive precursors. A good quantitative 
sure for the overall capacity of the stroma to support blood cell formation is the combined 
put of colony-forming cells in the non-adherent cell fraction and the adherent layer after a 
eek culture period (week 5 colony-forming cells, W5 CFC). Figure 4 shows W5 CFC 
bers from cultures of AML patients and controls. If one excludes the two patients with 
h W5 CFC numbers which were likely to originate from leukemic blasts, significantly 
reased W5 CFC numbers were observed in AML cultures in comparison to control 
ures (P = 0.009). 
  
rincipal, decreased numbers of W5 CFC can be related to decreased numbers of stem cells 
he initial inoculum or to a decreased hematopoiesis-supporting function of the stroma. The 
owing experiments were designed to detect abnormalities in the bone marrow stroma of 
ents with acute myeloid leukemia.  
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 Fig. 4: Numbers of week 5 colony-forming cells (W5 CFC) in long-term bone
marrow cultures from 6 AML patients and 9 controls.   
 
 
 
3.1.2 Two-stage long-term bone marrow cultures 
 
3.1.2.1 Hematopoiesis-supporting function of unfractionated bone marrow stroma 
When the adherent layer of the long-term cultures reached confluency, the flasks were 
irradiated with 15 Gy to eliminate endogenous blood cell formation. Then 2.5 x 104 purified 
CD34+ indicator cells were seeded on top of the irradiated stroma layer, and W5 CFC were 
determined as a measure of the hematopoiesis-supporting ability of the stroma.  
  
Figure 5 shows W5 CFC derived from AML and control two-stage cultures. In each of the 
two groups, the values obtained showed a significant degree of heterogeneity. There was no 
statistically significant correlation between the W5 CFC values and patient age, white blood 
cell count, cytogenetic abnormalities, stroma confluency or duration before complete 
remission (P = 0.069, 0.14, 0.15, 0.14 or 0.28, respectively). Since a considerable overlap was 
observed in the values obtained for AML versus control cultures, there was also no 
statistically significant difference in the W5 CFC numbers of the two patient groups (P = 0.1).  
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Fig. 5: Numbers of week 5 colony-forming cells (W5 CFC) in two-stage long-term bone
marrow cultures from 15 AML patients and 17 controls. After reaching confluency, the
cultures were irradiated with 15 Gy and overlaid with 2.5×104 CD34+ cells. Lines
represent median values. 
 
 
 
 
In view of its multicellular composition a normal overall stroma function does not necessarily 
mean that the function of its individual components is also unperturbed. To address this 
question the major stroma cell types, fibroblasts and macrophages, were isolated using 
immunomagnetic beads and analysed separately using W5 CFC output as an indicator for the 
hematopoisis-supporting ability of the cells. 
 
3.1.2.2 Fractionation of long-term bone marrow culture stroma  
Figure 6a shows a cytospin preparation of unfractionated trypsinized long-term culture 
stroma. The major discernible cell types are fibroblasts and macrophages. Figure 6b shows  
purified stroma macrophages and fibroblasts after immunomagnetic cell separation using the 
MACS device. The purity of the isolated cell populations was generally between 90 and 
100% (Table 8).  
 
 
  
 
Table 8: Purity of fibroblasts and macrophages
from trypsinized long-term culture stroma  
after immunomagnetic cell separation  
 
Population Macrophages 
(n=37) 
Fibroblasts 
(n=37) 
Purity 96.5 ± 2.5% 95.0 ± 3.0%
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Fig. 6a: May-Grünwald-Giemsa stained cytospin of unfractionated long-term bone
marrow culture stroma from a MDS patient. Cells with round heterochromatic nuclei and
vacuolated cytoplasm are macrophages (marked “m”), while those with larger irregular
euchromatic nuclei and blue cytoplasm are fibroblasts (marked “f” ).  
Original magnification *200. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6b: May-Grünwald-Giemsa stained cytospins of purified macrophages (left) or fibroblasts (right),
respectively,  from long-term bone marrow culture stroma. Original magnification *200. 
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3.1.2.3 Hematopoiesis-supporting function of stroma fibroblasts 
The bone marrow aspirates from 14 patients with AML and 11 controls were of sufficient 
quantity to allow the preparation of the required number of long-term cultures for stroma cell 
fractionation studies. Cell fractionation was not possible in patient no. 5 (RA) of the AML 
group and in patients no. 1 (SM), 3 (WKD), 12 (BM), 13 (RI), 15 (VL) and 17 (DB) of the 
controls (cf. Tables 3 and 5).  
 
After immunomagnetic separation fibroblasts were seeded in new culture flasks, allowed to 
reach confluency, and then overlaid with 2.5 × 104 normal CD34+ cells. W5 CFC numbers 
were used as a measure of the hematopoisis-supporting ability of the adherent layer. 
Confluency of the fibroblast layer was reached by the cells from all but one patient (AML 
patient no. 3 (DK), cf. Table 5). The hematopoiesis-supporting ability of this culture (310 W5 
CFC), however, was in the same range as that of the other AML samples (131 – 1723). 
 
 
862 
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Figure 7 shows W5 CFC numbers in two-stage cultures supported by purified fibroblasts 
from AML and control long-term bone marrow cultures. Although considerable 
heterogeneity was observed in both groups with respect to the numbers of W5 CFC, on the 
average AML fibroblasts showed a significantly lower capacity to support the growth of 
Fig. 7: Numbers of week 5 colony-forming cells (W5 CFC) in pure stroma fibroblast
cultures from 14 AML patients and 11 controls. After reaching confluency, the cultures
were overlaid with 2.5×104 CD34+ cells. Lines represent median values. 
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CD34+ cells than the fibroblasts from the controls (P = 0.018, Mann-Whitney U test). There 
was no correlation between the hematopoisis-supporting function of purified fibroblasts and 
the patient’s age, cytogenetic abnormalities, the degree of confluency of the adherent layer or 
the performance of the corresponding unfractionated adherent stroma layer. 
 
3.1.2.4 Hematopoiesis-supporting function of stroma macrophages 
An assessment of the hematopoiesis-supporting function of purified stroma macrophages 
requires different conditions from those used for stroma fibroblasts. Stroma macrophages are 
less frequent than stroma fibroblasts, they are virtually non-dividing failing to form a 
confluent adherent layer, and, if plated at low density, may be rapidly overgrown by small 
numbers of contaminating fibroblasts. To circumvent problems related to these properties 
purified macrophages were co-cultured with a confluent layer of irradiated murine M2-10B4 
cells which are known to support human hematopoiesis (Sutherland et al., 1991). These co-
cultures were then overlaid with 2.5 × 104 normal CD34+ indicator cells, and week 5 colony-
forming cells were determined to measure the hematopoiesis-supporting activity of the 
cultures. 
 
During the course of the experiments two different batches of M2-10B4 cells were used. The 
first batch used represented late passage cells that had been cultured in our laboratory for 
various purposes for several years. These cells showed slow growth, abnormal morphology on 
May-Grünwald-Giemsa-stained cytospins (large size, vacuolated cytoplasm, fragmented 
nucleus) and poor support of human CD34+ cells. Whether these properties were related to 
the age of the cell line or outgrowth of an abnormal subclone, remained unresolved. In order 
to improve the culture conditions a new cryopreserved batch was thawed and used in all 
subsequent experiments. The cells from this batch showed rapid growth and good support of 
CD34+ cells. In the subsequent description of the experiments, the first batch will be referred 
to as ‘late passage’ and the second one as ‘early passage’ M2-10B4 cells. The results obtained 
with the two types of cells are reported separately. Because in conjunction with macrophages 
early passage M2-10B4 cells were quite consistently about 9 times more active than late 
passage M2-10B4 cells, the results obtained with the two batches are also presented together 
by multiplying the values generated with late passage cells by 9. 
 
Figure 8a shows W5 CFC data obtained with late passage M2-10B4 cells. Although 55% of 
the AML cultures showed W5 CFC numbers above the range of the controls and the median 
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CFC numbers in the AML and control groups differed by more than two-fold (210 versus 98), 
these differences failed to reach statistical significance. 
98 
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Fig. 8a: Numbers of week 5 colony-forming cells (W5 CFC) in co-cultures of ‘late passage’ M2-
10B4 cells with stroma macrophages from 11 AML patients and 6 controls. The macrophages were
added to irradiated confluent M2-10B4 layers, and the cultures were overlaid with 2.5×104 CD34+
cells. Lines represent median values.  
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Fig. 8b: Numbers of week 5 colony-forming cells (W5 CFC) in co-cultures of ‘early passage’ M2-
10B4 cells with stroma macrophages from 4 AML patients and 11 controls. The macrophages were
added to irradiated confluent M2-10B4 layers, and the cultures were overlaid with 2.5×104 CD34+
cells. Lines represent median values.  
Figure 8b shows the W5 CFC data obtained with early passage M2-10B4 cells. Similar to the 
findings with late passage cells, 75% of the values in the AML group were above the range in 
the control group with a median of 1882 versus 875. In this set of experiments, statistical 
significance was demonstrated using the Mann-Whitney U test (P = 0.026). 
 
The ratio between the median W5 CFC numbers observed in the set of experiments using 
early passage M2-10B4 cells and the set of experiments using late passage M2-10B4 cells 
was almost identical in the AML group (8.96) and the control group (8.93). Assuming that 
early passage M2-10B4 cells are about 9 times more active than late passage M2-10B4 cells 
we multiplied the results obtained with late passage cells by this factor. Figure 8c shows the 
combined data of the two experimental periods in one graph. The combined set of data 
showed a statistically highly significant difference between the AML group and the control 
group (P = 0.008). Stroma macrophages from AML patients were significantly better 
supporters of hematopoiesis than stroma macrophages from individuals with a healthy bone 
marrow. This conclusion was confirmed by the aspect of the cultures under the inverted 
microscope. Cobble stone areas were more frequent and larger in M2-10B4 cultures 
containing AML macrophages than in cultures containing normal macrophages (Fig. 9).  
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Fig. 8c: Numbers of week 5 colony-forming cells (W5 CFC) in co-cultures of ‘early’ or ‘late passage’ M2-
10B4 cells with purified stroma macrophages from 15 AML patients and 17 controls. The macrophages
were added to irradiated confluent M2-10B4 layers, and the cultures were overlaid with 2.5×104 CD34+
cells. The data generated with cultures containing ‘late passage’ M2-10B4 cells were recalculated as
described in the text. Lines represent median values.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9: Co-cultures of M2-10B4 cells and purified stroma macrophages from a patient with AML (left panel) and
a control individual with a healthy bone marrow (right panel). The cultures were overlaid with 2.5×104 CD34+
cells and incubated for 5 weeks. M2-10B4 cells cover the bottom of the culture vessel as spindle-like structures,
macrophages are large round cells, and maturing hematopoietic cells can be seen on top of the adherent layer as
small shiny cells. The culture containing AML macrophages shows more abundant hematopoietic cells and, in
addition, a small cobble stone area (very small dark cells within the adherent layer; arrow).  
Phase-contrast inverted microscope, original magnification *100. 
 
In an effort to relate the behavior of stroma macrophages to other variables correlation 
analysis was performed testing the following factors: age, cytogenetic abnormalities, 
hematopoiesis-supporting ability of whole stroma and purified stroma fibroblasts, and 
duration before complete remission. No statistically significant correlations were observed.  
 
In order to exclude the possibility that the variability observed within the groups of AML 
patients and controls was related to technical problems occurring in the course of the complex 
cell culture procedure, parallel experiments were performed in two patients. A large bone 
marrow sample was used to prepare multiple primary long-term cultures. Each flask was 
handled separately including cell fractionation, co-culture of purified macrophages with M2-
10B4 cells and CD34+ cells, and determination of W5 CFC.  The results obtained for the two 
patients are shown in Tables 9a and 9b. The variation from flask to flask was small making 
technical reasons for the observed variability unlikely. 
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Table 9a. Reproducibility of the experimental procedure - experiment 1 
 
 Week 5 colony-forming cells 
Flask No. Supernatant Adherent layer Total 
1 464 966 1430 
2 535 663 1198 
3 549 1057 1606 
4 585 1002 1584 
5 529 943 1472 
6 493 990 1483 
Mean ± SD 525 ± 42 936 ± 139 1462 ± 146 
CV 8% 15% 9% 
 
 
 
 
Table 9b. Reproducibility of the experimental procedure - experiment 2 
 
 Week 5 colony-forming cells 
Flask No. Supernatant Adherent layer Total  
1 687 878 1565 
2 602 642 1244 
3 686 907 1593 
4 494 847 1341 
Mean ±SD 687 ± 91 819 ± 120 1436 ± 170 
CV 13% 15% 12% 
                                    SD: standard deviation; CV: constant variation (mean divided by SD) 
                                  
 
 
 
3.1.2.5 Influence of chemotherapy on stroma function  
In order to study the impact of chemotherapy on the hematopoiesis-supporting function of 
stroma cells, aspirates from 5 patients with AML (no. 1 [WL], no. 2 [TR], no. 6 [ME], no. 11 
[ZD] and no. 15 [BV]) were analysed before and after treatment of the patients. The only 
patient in complete remission at the time of the second analysis was patient no. 11.  
 
Figure 10a shows the function of unfractionated AML stroma before and after chemotherapy. 
A consistent decline was observed in the capacity of post-chemotherapy stroma to support the 
production of W5 CFC by normal CD34+ cells (P = 0.043, Wilcoxon test). In four of the 5 
patients studied a deterioration of stroma function was also observed when purified stroma 
fibroblasts were used as a support layer (Fig. 10b). Only the fibroblasts from patient no. 11 
showed an improved hematopoiesis-supporting capacity after chemotherapy. This result did 
not reach statistical significance.  
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Fig. 10a: Numbers of week 5 colony-forming cells (W5 CFC) in two-stage long-term cultures from 5
AML patients whose bone marrow was analysed both before and after chemotherapy. After reaching
confluency, the cultures were irradiated with 15 Gy and overlaid with 2.5×104 CD34+ cells. Numbers refer
to the patient code used in Table 5. 
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 Fig. 10b: Numbers of week 5 colony-forming cells (W5 CFC) in pure stroma fibroblast cultures from 5
AML patients whose bone marrow was analysed both before and after chemotherapy. After reaching
confluency, the cultures were overlaid with 2.5×104 CD34+ cells. Numbers refer to the patient code used in
Table 5. 
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Because the batch of M2-10B4 cells used for co-culture with macrophages was changed 
during the course of the experiments, pre- and post-chemotherapy macrophage function could 
only be compared in three patients (Fig. 10c). In all these cases a considerable decrease in the 
hematopoiesis-supporting function of the stroma macrophages was observed (P = 0.11). 
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Before After  
 Fig. 10c: Numbers of week 5 colony-forming cells (W5 CFC) in co-cultures of M2-10B4 cells with
stroma macrophages from 3 AML patients whose bone marrow was analysed both before and after
chemotherapy. The macrophages were added to irradiated confluent M2-10B4 layers, and the
cultures were overlaid with 2.5×104 CD34+ cells. Numbers refer to the patient code used in Table 5.
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3.2 Stroma function in myelodysplastic syndromes 
 
3.2.1 Hematopoiesis-supporting function of unfractionated bone marrow stroma 
 
To evaluate the hematopoiesis-supporting function of the entire bone marrow stroma, primary 
long-term cultures from bone marrow aspirates from 6 MDS patients were grown to 
confluency, irradiated and reseeded with purified CD34+ cells as described for the AML 
group. The control cultures were the same as those used in the AML study. The average 
confluency of the adherent layer in the MDS group was similar to that in the control group (67 
± 22% vs. 70 ± 28%). The numbers of W5 CFC in the MDS cultures were in the same range 
as those in the control cultures (Fig. 11). 
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 Fig. 11: Numbers of week 5 colony-forming cells (W5 CFC) in two-stage long-term bone marrow
cultures from 6 MDS patients and 17 controls. Five MDS patients had prognostically favorable
subtypes of the disease and one (open circle) had refractory anemia with excess of blasts (cf. Table 6).
After reaching confluency, the cultures were irradiated with 15 Gy and overlaid with 2.5×104 CD34+
cells. Lines represent median values. 
 
 
 
 
 
 
 39
3.2.2 Hematopoiesis-supporting function of stroma fibroblasts 
 
Fibroblasts were purified from confluent stroma of long-term cultures, recultured until 
confluency, and then overlaid with CD34+ indicator cells. Five of six fibroblast cultures 
reached confluency while the fibroblasts layer from one patient (no. 2 [TG], cf. Table 6) was 
too sparse to be able to serve as a support layer for CD34+ cells. Although the range of W5 
CFC numbers from MDS and control cultures showed some overlap, a statistically significant 
impairment of the hematopoiesis-supporting function was seen in the group of MDS cultures 
(P = 0.038; Fig. 12). 
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 Fig. 12: Numbers of week 5 colony-forming cells (W5 CFC) in pure stroma fibroblast cultures from
5 MDS patients and 11 controls. Four MDS patients had prognostically favorable subtypes of the
disease and one (open circle) had refractory anemia with excess of blasts (cf. Table 6). After
reaching confluency, the cultures were overlaid with 2.5×104 CD34+ cells. Lines represent median
values. 
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3.2.3 Hematopoiesis-supporting function of stroma macrophages 
 
Purified stroma macrophages were co-cultured with M2-10B4 cells as described for the group 
of AML patients, and evaluated for their ability to support the development of W5 CFC from 
added CD34+ cells. Figure 13 summarizes the results for those 5 MDS cultures that were 
prepared using early passage M2-10B4 cells. There were no significant differences between  
MDS cultures and controls. The results of the only patient (no. 4 [PM]) studied with late 
passage M2-10B4 cells are not shown.  
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 MDS Controls 
Fig. 13: Numbers of week 5 colony-forming cells (W5 CFC) in co-cultures of ‘early passage’ M2-10B4
cells with stroma macrophages from 5 MDS patients and 11 controls. Four MDS patients had prognostically
favorable subtypes of the disease and one (open circle) had refractory anemia with excess of blasts (cf.
Table 6). The macrophages were added to irradiated confluent M2-10B4 layers, and the cultures were
overlaid with 2.5×104 CD34+ cells. Lines represent median values.
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3.3 Stroma function in multiple myeloma 
 
3.3.1 Hematopoiesis-supporting function of unfractionated bone marrow stroma 
 
To evaluate the hematopoiesis-supporting function of the entire bone marrow stroma, primary 
long-term cultures from bone marrow aspirates from 9 multiple myeloma patients were grown 
to confluency, irradiated and reseeded with purified CD34+ cells as described for the AML 
group. The control cultures were the same as those used in the AML and MDS studies. The 
average confluency of the adherent layer in the multiple myeloma group was similar to that in 
the control group (67 ± 34% vs. 70 ± 28%). The numbers of W5 CFC in the multiple 
myeloma cultures were in the same range as those in the control cultures (Fig. 14). 
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 Fig. 14: Numbers of week 5 colony-forming cells (W5 CFC) in two-stage long-term bone marrow
cultures from 9 multiple myeloma (MM) patients and 17 controls. After reaching confluency, the
cultures were irradiated with 15 Gy and overlaid with 2.5×104 CD34+ cells. Lines represent median
values. 
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3.3.2 Hematopoiesis-supporting function of stroma fibroblasts 
 
Fibroblasts were purified from confluent stroma of long-term cultures from 7 multiple 
myeloma patients, recultured until confluency, and then overlaid with CD34+ indicator cells. 
In two patients (no. 3 [PL] and no. 9 [SK], cf. Table 7) the cellularity of the marrow aspirate 
was insufficient to allow the establishment of long-term cultures for fibroblast purification. 
Although the range of W5 CFC values in the group of MM cultures appeared to be somewhat 
wider than in the controls, a statistically significant difference between the two groups was 
not observed (Fig. 15). 
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Fig. 15: Numbers of week 5 colony-forming cells (W5 CFC) in pure stroma fibroblast cultures from 7
multiple myeloma (MM) patients and 11 controls. After reaching confluency, the cultures were overlaid
with 2.5×104 CD34+ cells. Lines represent median values. 
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3.3.3 Hematopoiesis-supporting function of stroma macrophages 
 
Purified stroma macrophages from 8 multiple myeloma patients were co-cultured with M2-
10B4 cells as described for the group of AML patients, and evaluated for their ability to 
support the development of W5 CFC from added CD34+ cells. In one patients (no. 5 [KC], cf. 
Table 7) the cellularity of the marrow aspirate was insufficient to allow the establishment of 
long-term cultures for macrophage purification. Similar to the investigation in AML patients, 
two different batches of M2-10B4 cells of differing hematopoiesis-supporting potential were 
used in these experiments. Figure 16a summarizes the results for the cultures prepared with 
late passage M2-10B4 cells, and Figure 16b shows the results obtained with early passage 
M2-10B4 cells. In neither of the two sets of experiments were significant differences 
observed between multiple myeloma and control cultures. The ratio between the median W5 
CFC numbers observed in the set of experiments using early passage M2-10B4 cells and the 
set of experiments using late passage M2-10B4 cells was similar in the groups of multiple 
myeloma patients (7.72) and controls (8.93). The results of the two sets of experiments were 
therefore combined by mathematical recalculation of the data, as described in the AML 
section. Again, there were no significant differences between multiple myeloma cultures and 
controls (Fig. 16c). 
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Fig. 16a: Numbers of week 5 colony-forming cells (W5 CFC) in co-cultures of ‘late passage’ M2-10B4 cells
with stroma macrophages from 4 multiple myeloma (MM) patients and 6 controls. The macrophages were
added to irradiated confluent M2-10B4 layers, and the cultures were overlaid with 2.5×104 CD34+ cells.
Lines represent median values.  
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Fig. 16b: Numbers of week 5 colony-forming cells (W5 CFC) in co-cultures of ‘early passage’ M2-10B4
cells with stroma macrophages from 4 multiple myeloma (MM) patients and 11 controls. The
macrophages were added to irradiated confluent M2-10B4 layers, and the cultures were overlaid with
2.5×104 CD34+ cells. Lines represent median values. 
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Fig. 16c: Numbers of week 5 colony-forming cells (W5 CFC) in co-cultures of ‘early’ or ‘late passage’
M2-10B4 cells with purified stroma macrophages from 8 multiple myeloma (MM) patients and 17
controls. The macrophages were added to irradiated confluent M2-10B4 layers, and the cultures were
overlaid with 2.5×104 CD34+ cells. The data generated with cultures containing ‘late passage’ M2-10B4
cells were recalculated as described in the text. Lines represent median values. 
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3.4 Differences in the hematopoiesis-supporting function of early versus late passage 
M2-10B4 cells 
 
As mentioned in section 3.1.2.4, a fresh batch of M2-10B4 cells was thawed in the course of 
the experiments because the originally used cells grew poorly and provided weak support for 
co-cultured CD34+ cells. The new batch termed ‘early passage’ M2-10B4 cells was about 9-
times more potent in supporting blood cell formation in conjunction with human macrophages 
than the original batch referred to as ‘late passage’ cells. Interestingly, the two batches of M2-
10B4 cells did not only differ quantitatively with respect to their ability to support 
hematopoesis, but they also differentially affected the behavior of co-cultured macrophages 
and the ratio between precursor cells and non-adherent end cells in the cultures which reflects 
the balance between stem cell maintenance and differentiation. 
 
The differential effect of the two batches of M2-10B4 cells on co-cultured macrophages 
became apparent when the hematopoiesis-supporting capacity of M2-10B4 cultures 
supplemented with macrophages were compared with that of control cultures containing M2-
10B4 cells alone (Figs. 17a and b). In M2-10B4 control cultures the median number of W5 
CFC per flask was 174 for late passage and 306 for early passage M2-10B4 cells. Figure 17 
depicts the ratio between W5 CFC numbers in macrophage-supplemented cultures and their 
respective M2-10B4 only controls. A ratio below 1 signifies a detrimental effect of 
macrophages on M2-10B4-mediated stem cell maintenance, while a ratio above 1 means that 
macrophages enhance the stem cell-supporting effect of M2-10B4 cells. With late passage 
M2-10B4 cells, an inhibitory effect of co-cultured macrophages on stem cell maintenance was 
observed in the majority of cultures (Fig. 17a). By contrast, when early passage M2-10B4 
cells were used as a feeder layer, the addition of macrophages almost invariably led to 
improved stem cell maintenance. As described in sections 3.1.2.4, 3.2.3 and 3.3.3, stroma 
macrophages from AML patients had a significantly stronger potency to support the 
development of W5 CFC than macrophages from controls (Figs. 8a-c) or patients with MDS 
(Fig. 13) or multiple myeloma (Figs.16a-c). 
 
The number of non-adherent cells in the supernatant reflects the productivity of the long-term 
culture which is a function of the number of stem cells in the stroma layer and the number of 
mature cells produced by each stem cell. In M2-10B4 control cultures the median number of 
non-adherent cells per flask at week 5 was 0.20 x 105 for late passage and 0.80 x 105  for early 
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passage M2-10B4 cells. Figures 18a and b show that the addition of human macrophages to 
the adherent layer increased the production of mature cells irrespective of the batch of M2-
10B4 cells used.  
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Fig. 17a: Ratio of W5 CFC in ‘late passage’ M2-10B4 cultures supplemented with 2.5x104 CD34+ cells
plus 3x105 macrophages and M2-10B4 cultures supplemented with CD34+ cells alone. The median
absolute W5 CFC number in M2-10B4 cultures supplemented with CD34+ cells alone was 174 per flask
(range 50-271). 
Controls MMMDSAML 
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AML MDS MM Controls 
Fig. 17b: Ratio of W5 CFC in ‘early passage’ M2-10B4 cultures supplemented with 2.5x104 CD34+
cells plus 3x105 macrophages and M2-10B4 cultures supplemented with CD34+ cells alone. The
median absolute W5 CFC number in M2-10B4 cultures supplemented with CD34+ cells alone was 306
per flask (range 254-889). 
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Fig. 18a: Ratio of total non-adherent cells at week 5 in ‘late passage’ M2-10B4 cultures supplemented
with 2.5x104 CD34+ cells plus 3x105 macrophages and M2-10B4 cultures supplemented with CD34+
cells alone. The median absolute number of non-adherent cells in M2-10B4 cultures supplemented with
CD34+ cells alone was 0.20x105 per flask (range 0.06-0.45x105).
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Fig. 18b: Ratio of total non-adherent cells at week 5 in ‘early passage’ M2-10B4 cultures supplemented with
2.5x104 CD34+ cells plus 3x105 macrophages and M2-10B4 cultures supplemented with CD34+ cells alone.
The median absolute number of non-adherent cells in M2-10B4 cultures supplemented with CD34+ cells
alone was 0.80x105 per flask (range 0.02-1.89x105). 
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The relation between the number of total non-adherent cells in the supernatant at week 5 and 
the number of W5 CFC indicates the balance between stem cell differentiation and 
maintenance. When early passage M2-10B4 cells which provide favorable conditions for stem 
cell maintenance were used as a feeder layer, macrophages did not significantly perturb the 
ratio between stem cell maintenance and differentiation (Fig. 19). By contrast, in poor culture 
conditions provided by late passage M2-10B4 cells, a striking difference was observed 
between the function of macrophages from AML patients and macrophages from controls or 
patients with MDS or multiple myeloma. While the latter appeared to promote differentiation, 
AML macrophages seemed to favor maintenance of stem cells (Fig. 19). 
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alone   
Fig. 19: Ratio between total non-adherent cells at week 5 and W5 CFC in ‘early’ or ‘late
passage’ M2-10B4 cultures supplemented with 2.5x104 CD34+ cells plus 3x105 macrophages
(designated AML, MDS, MM or controls, respectively) or CD34+ cells without macrophages
(designated M2-10B4 alone). Means ± standard deviation. Note the difference in the behavior
of AML macrophages and all other types of macrophages in cultures prepared with ‘late
passage’ M2-10B4 (P = 0.034). 
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4   Discussion 
 
 
The long-term bone marrow culture system is regarded as the best in vitro model for 
hematopoiesis. In this culture system, hematopoietic stem cells reside in the stromal 
microenvironment where they proliferate and differentiate. Maturing progeny and post-
mitotic end cells are then released into the culture medium. A well-balanced interaction 
between hematopoietic cells and stroma cells is a prerequisite to sustain long-term 
hematopoiesis. Maintenance of hematopoiesis for prolonged periods of time does not only 
depend on the quantitative and qualitative state of hematopoietic stem cells, but also on the 
function of the stromal microenvironment. 
 
One of the major drawbacks of the long-term culture system is the fact that, even if the 
experimental conditions are strictly standardized and homogeneous populations of cells from 
healthy individuals or patients are analysed, the results may be quite variable. The reason for 
this variability which may have prevented a more wide-spread use of the system in 
experimental hematology, is not entirely understood. Although a high degree of heterogeneity 
was also observed in the study presented here, the results demonstrate clear differences in the 
behavior of stroma fibroblasts and/or macrophages from patients with myeloid malignancies 
as compared to the respective cells from individuals with a healthy bone marrow or multiple 
myeloma. 
 
 
4.1 Function of bone marrow stroma cells in acute myeloid leukemia 
 
In primary long-term cultures of AML bone marrow, two patterns of progenitor cell growth 
were observed highlighting the heterogeneity of the disease. These findings are in line with 
those reported by Coulombel et al. (Coulombel et al., 1985). When cultures with an obvious 
overgrowth of leukemic cells were excluded from the analysis, a more homogeneous pattern 
with decreased numbers of progenitor cells was observed, implying that normal 
hematopoiesis is suppressed in long-term cultures from AML bone marrow. Three possible 
reasons may contribute to this result: First, although the same numbers of mononuclear cells 
were seeded initially in AML and control cultures, a preponderance of leukemic blasts in the 
AML cultures may dilute the frequency of stem cells with the potential to maintain long-term 
blood cell formation. Second, leukemic cells have been reported to produce inhibitory factors 
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interfering with the proliferation of normal hematopoietic cells. And third, abnormalities in 
the stromal microenvironment may exist in AML. Our investigation focussed on the last 
named mechanism. Using stroma layers depleted of hematopoietic and leukemic cells by 
irradiation or immunomagnetic cell separation and reseeded with a standardized inoculum of 
normal CD34+ cells, we were able to analyse the hematopoiesis-supporting function of 
unfractionated stroma or purified stroma cell components without the confounding effects of 
co-cultured leukemic cells. 
 
The function of the entire unfractionated bone marrow microenvironment was analysed by 
employing  the two-stage culture model with irradiated stroma layers. Using this assay system 
we were unable to detect significant differences between AML stroma and stroma from 
healthy bone marrow. In contrast to our results, other reports hint at an altered function of 
long-term culture stroma from AML patients. Mayani et al. used normal bone marrow buffy 
coat cells depleted of adherent cells as indicator cells for the hematopoiesis-supporting 
function of AML stroma and observed a decreased W5 CFC output compared to normal 
stroma (Mayani et al., 1992a). The decrease in hematopoiesis-supporting capacity correlated 
with increased levels of TNF-α in the culture medium which was thought to be the main 
inhibitory factor. By contrast, Dührsen et al. used cells of the transplantable murine leukemia 
PGM-1 as indicator cells for stroma function and observed a heightened PGM-1-supporting 
ability of AML stroma as compared to normal stroma (Dührsen et al., 1995). The picture 
emerging from this discrepancy is that AML stroma may stimulate the production of leukemic 
cells at the expense of normal blood cells. It cannot be ruled out, however, that differences in 
the patient population studied or the culture conditions chosen also contributed to the 
disparity of the results. 
  
The hematopoietic microenvironment is composed of several types of cells which are 
involved in the regulation of hematopoiesis by direct cell-cell contact, production of cytokines 
or elaboration of an extracellular matrix. Every cell component contributes to the global 
function of the entire stroma. In order to clarify whether the seemingly unperturbed function 
of the unfractionated stroma layer in AML was due to an unperturbed function of its 
individual cellular constituents or to mutual compensation of functional alterations of 
different stroma components, the main cell types of the stroma, fibroblasts and macrophages, 
were purified from the adherent layer and analysed separately. 
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In contrast to the function of the intact stroma layer, the hematopoiesis-supporting ability of 
purified fibroblasts was shown to be decreased in the AML group. The decrease was not due 
to insufficient fibroblast numbers because, in all but one of the AML patients, the isolated 
fibroblasts could form a confluent adherent layer. Our result is in keeping with the report by 
Greenberg et al. who also demonstrated a deficient ability of the fibroblast layers from AML 
patients to support hematopoiesis in vitro (Greenberg et al., 1981). The functional deficiency 
has been shown to be associated with an abnormal expression of cytokines including IL-1β, 
IL-6, G-CSF and leukemia inhibitory factor (LIF) (Denkers et al., 1992; Wetzler et al., 1995) 
and a reduced membrane expression of certain adhesion molecules (Denkers et al., 1992; 
Wetzler et al., 1995). The abnormal function may be orchestrated by coexisting leukemic cells. 
Inhibitory effects on fibroblast precursors by AML cells, AML cell-conditioned medium, and 
AML serum have been reported (Nagao et al., 1983b; Nara et al., 1984). In the experiments 
presented here, however, significant numbers of contaminating AML cells were not present in 
the population of purified fibroblasts. Therefore, a more likely explanation for the functional 
abnormalities is the assumption that the establishment of an AML cell population in the bone 
marrow leads to a shift in the relative frequency of different types of stroma fibroblasts which 
results in a decreased hematopoiesis-supporting ability in the long-term culture system. This 
assumption is supported by evidence from other investigators (Dührsen and Hossfeld, 1996; 
Greenberg et al., 1984). 
  
Isolated stroma macrophages are unable to form a confluent adherent layer and maintain long-
term hematopoiesis. We therefore studied their function in the control of blood cell formation 
by standardized co-culture with a confluent layer of irradiated M2-10B4 cells. M2-10B4 is a 
murine bone marrow fibroblast cell line which, despite its inability to secrete human 
hematopoietic growth factors, can sustain human long-term hematopoiesis as effectively as 
human fibroblasts (Sutherland et al., 1991). Its use as a feeder layer satisfied the following 
requirements:  
1. Preliminary experiments showed that the presence of minute numbers of 
contaminating fibroblasts within the population of purified macrophages resulted in 
rapid overgrowth of this highly proliferating cell type. Since the growth and survival 
of fibroblasts in vitro is dependent on adherence to plastic, we reasoned that a pre-
established layer of M2-10B4 cells would deprive the fibroblasts of anchor sites on the 
bottom of the culture flask thus preventing their proliferation.  
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2. Preliminary experiments also showed that a substantial proportion of purified 
macrophages died after transfer to a new flask and subsequent culture at low cell 
density. Transfer of the cells to a flask with a pre-established layer of M2-10B4 cells 
resulted in substantially improved macrophage survival.  
3. The type of feeder layer used for the study of macrophage function had to be kept 
constant throughout the investigation. Since M2-10B4 is a continuous cell line, there 
were always sufficient cells for the experiments. 
To our knowledge, our approach to study the function of isolated stroma macrophages in co-
culture with a standard adherent layer, has not been taken before. Although a considerable 
amount of heterogeneity was observed, the assay system permitted the detection of a 
significantly heightened hematopoiesis-supporting function of macrophages from AML 
patients as compared  to the cells from controls or patients with myelodysplastic syndromes or 
multiple myeloma. 
 
Our findings are somewhat similar to those of Mayani et al. who observed an increased W5 
CFC output in two-stage long-term cultures from AML bone marrow when macrophage 
colony-stimulating factor was added during the development of the adherent layer (Mayani et 
al., 1992c). This cytokine induced the growth of increased numbers of macrophages which 
were supposed to be of leukemic origin. The authors interpreted their observation as a reduced 
capacity of leukemic (as opposed to normal) macrophages to produce the hematopoietic 
inhibitor TNF-α  (Mayani et al., 1992c). These findings contrast with those of Greenberg et al. 
who used monocyte-macrophage populations from AML patients and controls to stimulate the 
growth of progenitor cells in agar cultures (Greenberg et al., 1978). Cells of AML origin 
provided a lower capacity to promote granulocyte colony formation than cells from controls, 
with an improvement in macrophage function upon achievement of disease remission. The 
discrepancy between the results reported by Mayani et al. and Greenberg et al. was probably 
related to the fact that their assay systems were not identical. 
 
Since stroma macrophages are of hematopoietic origin, it is conceivable that, in patients with 
AML, they are part of the leukemic clone. A leukemic origin of marrow macrophages has 
been demonstrated in several instances of acute myeloid leukemia (Langley et al., 1986; 
Zhang et al., 1999). A systematic study using cytogenetic markers, however, revealed that, in 
most cases of AML, the majority of stroma macrophages is not derived from the leukemic 
clone (Zhang et al., 1999). 
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The simplest explanation for our findings is the assumption that, in patients with AML, a 
decrease in the hematopoiesis-supporting function of stroma fibroblasts was compensated for 
by an increase in the hematopoiesis-supporting function of stroma macrophages. Overall, the 
hematopoiesis-supporting ability of the unfractionated stroma layer was not significantly 
different from that of patients with a healthy bone marrow. Our results show that, even if no 
abnormal function is detected in the unfractionated stroma layer, an abnormality may still 
exist in specific stroma components. These may exert unusual regulatory effects possibly 
promoting the growth of leukemic and inhibiting the growth of normal hematopoietic cells 
(Dührsen and Hossfeld, 1996). 
 
In 5 patients with AML, the function of the bone marrow stroma was analysed both before 
and after administration of chemotherapy. All patients experienced a decrease in the 
hematopoiesis-supporting function of unfractionated stroma and purified stroma macrophages, 
and all but one also showed a decrease in the function of purified stroma fibroblasts after 
chemotherapy. Interestingly, the patient whose fibroblast function improved following 
chemotherapy was the only one to attain complete remission. While the small number of 
patients included in this part of the study precludes a meaningful interpretation of the results, 
disease stage-dependent fluctuations in stroma function or composition have also been 
reported by other investigators (Greenberg et al., 1981; Kaneko et al., 1982; Katsuno et al., 
1986; Nagao et al., 1983a). The numbers of fibroblast precursors (colony-forming unit-
fibroblast, CFU-F) and the support function of fibroblast layers were decreased at initial 
diagnosis and relapse, and recovered to almost normal levels at remission. Although 
chemotherapy may improve the function of the hematopoietic microenvironment by 
eliminating neoplastic cells, its predominant effect is deterioration of stroma function which is 
probably related to its cytotoxic properties. This has most convincingly been demonstrated in 
patients receiving myeloablative therapy prior to autologous or allogeneic stem cell 
transplantation (Galotto et al., 1999).  
 
 
4.2 Function of bone marrow stroma cells in myelodysplastic syndromes 
 
The term ‘myelodysplastic syndrome’ encompasses a heterogeneous group of hematopoietic 
malignancies which is subdivided on morphological grounds according to the French-
American-British classification (Bennett et al., 1982). The biological behavior - as evidenced 
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by the response to therapy, the duration of survival or the rate of transformation to acute 
leukemia - varies greatly among different subtypes. Not surprisingly, the results of 
experimental studies on the biology of MDS are characterized by a substantial degree of 
heterogeneity.  
 
Similar to the findings in AML, considerable variability was also observed in the behavior of 
long-term cultures from patients with MDS. No statistically significant abnormalities were 
detected when unfractionated stroma or isolated stroma macrophages were analysed. With 
regard to unfractionated stroma our findings are confirmed by several reports from other 
researchers (Coutinho et al., 1990; Milner et al., 1977; Ruutu et al., 1984). The lack of 
evidence for abnormalities in the hematopoiesis-supporting function of MDS stroma was 
paralleled by an inability to detect abnormalities in its cytokine expression pattern (Hirayama 
et al., 1993). Other authors, however, reported a decreased hematopoiesis-supporting function 
of bone marrow stroma from MDS patients (Aizawa et al., 1999; Tennant et al., 2000). This 
controversy is most likely related to differences in patient populations studied and 
experimental conditions chosen. The same may be true for a report of an aberrant macrophage 
function in MDS patients characterized by increased production of inhibitory cytokines upon 
stimulation with GM-CSF (Ohmori et al., 1990).  
 
The only abnormality to be detected in our analysis in MDS patients was a decreased 
hematopoiesis-supporting ability of purified stroma fibroblasts. The most dramatic decrease 
was observed in a patient with refractory anemia with excess of blasts, a subtype of MDS with 
a very high likelihood to proceed to acute myeloid leukemia. Abnormalities in the behavior of 
stroma fibroblasts from MDS patients have also been reported by other investigators. Several 
groups reported a reduced frequency of CFU-F or an incomplete confluency of the adherent 
layer in long-term bone marrow cultures indicative of a defect in cell survival or proliferation 
(Borbenyi et al., 1987; Coutinho et al., 1990; Zipori et al., 1985). Failure to develop a 
confluent adherent layer was also observed in a culture of purified fibroblasts from one of our 
patients. The reduced hematopoiesis-supporting function of MDS fibroblasts may be related 
to the ability of stroma cells from some MDS patients to induce apoptosis in hematopoietic 
cells (Aizawa et al., 1999; Aizawa et al., 2000; Tauro et al., 2002). Furthermore, stroma cells 
from MDS patients may show abnormal cytokine expression, including an increased 
expression of IL-1β, TGF-β, IL-6 and LIF and a decreased expression of IL-1α receptor 
antagonist (Raza et al., 1995a; Raza et al., 1995b; Wetzler et al., 1995). There may also be 
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abnormal adhesive interactions and abnormalities in the composition of the extracellular 
matrix which is, to a large extent, produced by stroma fibroblasts. The prognostically 
unfavorable occurrence of ‘atypically located immature precursors’ (ALIPs) which is reported 
in about 60% of MDS cases may be related to such abnormal interactions between 
hematopoietic cells and stroma fibroblasts (Tricot et al., 1984).  
 
 
4.3 Function of bone marrow stroma cells in multiple myeloma 
 
To keep the results comparable with the AML and MDS groups, we also used Dexter-type 
long-term cultures (Dexter et al., 1977) to study stroma function in multiple myeloma patients. 
Multiple myeloma is a human B-cell neoplasm. The use of Dexter-type cultures which is 
conducive to the establishment of myeloid hematopoiesis may prevent the detection of 
abnormalities related to lymphoid hematopoiesis. Therefore, our results do not exclude the 
possibility that culture conditions promoting the growth of lymphoid cells (Whitlock and 
Witte, 1982) would have led to the development of an adherent layer with different properties. 
 
Irrespective of the composition of the stromal support layer (unfractionated stroma, purified 
fibroblasts, purified macrophages co-cultured with M2-10B4 cells), differences between 
multiple myeloma cultures and cultures established from healthy bone marrow were not 
observed. Subtle differences in fibroblast function described by others (Gregoretti et al., 1994), 
such as a reduced deposition of extracellular matrix proteins, remained undetectable in our 
assay system.  
 
 
 
4.4 Fibroblast heterogeneity as demonstrated by differing functional properties of 
early versus late passage M2-10B4 cells 
 
An unexpected side finding of our study was the observation that M2-10B4 cells of dissimilar 
age differed in their capacity to support hematopoiesis. In addition, the batch of M2-10B4 
cells used had a strong influence on the behavior of co-cultured human macrophages and the 
relation between the numbers of immature precursors (W5 CFC) and mature end cells at the 
end of the 5-week culture period. 
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When late passage M2-10B4 cells were used in conjunction with normal macrophages, the 
relation between W5 CFC and mature cells was shifted towards the latter, indicating limited 
self-renewal and preferential differentiation of stem cells. By contrast, with early passage M2-
10B4 cells co-cultured with normal macrophages, the ratio was shifted towards W5 CFC. In 
these cultures there were also very high cell numbers in the supernatant indicating both 
increased stem cell maintenance and enhanced proliferation of differentiated cells. A model 
explaining these results is shown in Figure 20.  
 s 
 
 
 
 
 
 
 
 
 
 
 Figure 20: Interactions between M2-10B4 stroma fibroblasts, human stroma macrophages and
hematopoietic cells. “+” indicates stimulatory signals which promote differentiation; “-” indicates
inhibitory signals which inhibit differentiation but sustain the stem cell pool. 
 
 
Hematopoietic stem cells are supposed to be located in specific stem cell niches composed of 
stroma cells and their products.  In long-term bone marrow cultures stem cells remain in a 
quiescent state only to enter the cell cycle upon change of the culture medium (Cashman et al., 
1999). If daughter cells associate with another stem cell niche, they also stay in a non-cycling 
state thus maintaining the stem cell pool. If they are exposed to a part of the 
microenvironment which does not contain a stem cell niche, they differentiate, proliferate and 
finally migrate into the culture medium (Verfaillie, 1998). Late passage M2-10B4 cells may 
have an impaired ability to provide sufficient niches for stem cells, so stem cells will undergo 
differentiation and maturation under the influence of soluble factors provided by co-cultured 
human macrophages. The result of such culture conditions is decreased stem cell maintenance 
with an increased proportion of mature cells in the supernatant. By contrast, early passage 
M2-10B4 cells appear to be able to provide enough niches for dividing stem cells thus 
maintaining and expanding the pool of early precursors. When their daughter cells are hit by 
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mediators from human macrophages they proliferate and differentiate to more mature cells 
which are eventually released into the supernatant. As a result, both increased stem cell 
maintenance and increased production of differentiated progeny are demonstrable in these 
cultures.   
 
In contrast to macrophages from healthy bone marrow, macrophages from AML marrow 
tended to promote maintenance rather than differentiation of stem cells. Whether the 
stimulation of self-renewal extends to leukemic stem cells which could contribute to an 
amplification of the leukemic clone, remains to be demonstrated.  
 
 
4.5 Conclusions and outlook 
 
Using the two-stage long-term culture system as an instrument to analyse stroma function 
without the confounding effects of benign or malignant hematopoietic cells we were able to 
demonstrate a decreased hematopoiesis-supporting function of fibroblasts from patients with 
AML and MDS and an increased hematopoiesis-supporting function of macrophages from 
patients with AML in comparison to the respective stroma cell types from individuals with a 
healthy bone marrow or multiple myeloma. Although these differences reached statistical 
significance, the variability observed within the groups of patients with AML or MDS 
suggests that some patients harbor stroma cells with abnormal properties whereas, in others, 
cell function may still be normal. The major questions arising from these results concern the 
clonal origin of the abnormal cells and the molecular basis of their perturbed function. During 
the course of our experiments cytospins were prepared and RNA was extracted from purified 
stroma cell populations whenever the volume of the initial bone marrow aspirate permitted 
such preparations. Our future work will be directed at analysing these samples by interphase 
fluorescence in situ hybridisation with chromosome probes specific for the cytogenetic 
abnormalities of the respective diseases and by establishing gene expression profiles using 
microarray technology. It is hoped that these studies will provide further insight into the 
abnormalities of the bone marrow microenvironment in hematological malignancies. 
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5 Summary 
 
The long-term bone marrow culture system is the most frequently used in vitro model for 
hematopoiesis. In this system, the adherent layer, composed of stroma cells of non-
hematopoietic (fibroblasts, adipocytes, endothelial cells) or hematopoietic origin 
(macrophages) and their products (adhesion molecules, cytokines, extracellular matrix), 
constitutes the hematopoietic microenvironment which orchestrates the proliferation, 
differentiation and maturation of hematopoietic stem cells and their progeny.  
 
To investigate stroma function in hematological malignancies, we established long-term bone 
marrow cultures from 21 untreated patients with acute myeloid leukemia (AML), 6 untreated 
patients with myelodysplastic syndromes (MDS), 9 untreated patients with multiple myeloma 
and 28 controls, and measured the hematopoiesis-supporting ability of the stroma by 
determining the number of colony-forming cells in the adherent layer and the supernatant 
after 5 weeks’ of culture (W5 CFC). In order to study stroma function without the 
confounding effects of endogenous benign or malignant hematopoietic cells the cultures were 
either irradiated or stroma fibroblasts and macrophages were purified using immunomagnetic 
techniques. While stroma fibroblasts could be used directly as a support layer for co-cultured 
CD34+ indicator cells, purified stroma macrophages were unable to form a confluent adherent 
layer and had to be analysed in conjunction with irradiated murine M2-10B4 cells. 
 
In contrast to purified fibroblasts from healthy or multiple myeloma bone marrow, fibroblasts 
from AML and MDS marrow showed a significantly reduced capacity to support blood cell 
formation. The hematopoiesis-supporting ability of stroma macrophages from AML marrow 
was markedly enhanced in comparison to macrophages from MDS, multiple myeloma or 
control marrow. Although the results were statistically significant, considerable overlap was 
observed in the range of activities of stroma cells from controls and patients, suggesting that 
the occurrence of functionally abnormal cells was limited to a subfraction of AML and MDS 
patients. Longitudinal studies showed that chemotherapy of patients was followed by a 
deterioration of stroma function. 
 
The function of stroma fibroblasts and macrophages is markedly perturbed in a substantial 
proportion of patients with myeloid malignancies. The major questions arising from these 
observations concern the clonal origin of the abnormal cells and the molecular basis of their 
perturbed function.  
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